Prohibits drug, cannabis or alcohol testing of pregnant or postpartum individuals and newborns unless the individual consents and it is within the scope of medical care, or the testing is necessary for a medical emergency.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Requires hospitals to obtain verbal and written informed consent from a patient or representative before including such patient's information in a general hospital facility directory.
Requires hospitals to obtain verbal and written informed consent from a patient or representative before including such patient's information in a general hospital facility directory.
Enacts the "foreign drug transparency act" to provide information on the origin, manufacture and distribution of prescription drugs; requires a pharmacy benefit manager to maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.
Enacts the "foreign drug transparency act" to provide information on the origin, manufacture and distribution of prescription drugs; requires a pharmacy benefit manager to maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.
Allows camp employees to administer medications and treatment to children, under parent or guardian consent and authorization, pursuant to a patient specific order and in compliance with regulations.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.